DRUG (Bright Minds Biosciences Inc. Common Stock) Stock Analysis - Analyst Ratings

Bright Minds Biosciences Inc. Common Stock (DRUG) is a publicly traded Healthcare sector company. As of May 21, 2026, DRUG trades at $83.00 with a market cap of $734.04M and a P/E ratio of 0.00. DRUG moved +11.07% today. Year to date, DRUG is +3.46%; over the trailing twelve months it is +155.02%. Its 52-week range spans $0.94 to $123.75. Analyst consensus is strong buy with an average price target of $145.67. Rallies surfaces DRUG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate DRUG?

3 analysts cover DRUG: 0 strong buy, 3 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $145.67.

DRUG Key Metrics

Key financial metrics for DRUG
MetricValue
Price$83.00
Market Cap$734.04M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$123.75
52-Week Low$0.94
Volume41
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

DRUG Analyst Consensus

3 analysts cover DRUG: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $145.67.

Latest DRUG News

Recent DRUG Insider Trades

  • Cormorant Asset Management, LP sold 109.33K (~$9.79M) on Apr 28, 2026.
  • Cormorant Asset Management, LP bought 184.33K (~$4.00M) on Nov 4, 2024.
  • Cormorant Asset Management, LP bought 39.74K (~$922.63K) on Oct 16, 2024.

Common questions about DRUG

What do analysts rate DRUG?
3 analysts cover DRUG: 0 strong buy, 3 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $145.67.
Does Rallies show DRUG price targets?
Yes. Rallies tracks DRUG analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is DRUG research on Rallies investment advice?
No. Rallies provides research, data, and educational context for DRUG. It does not provide personalized investment advice.
DRUG

DRUG